ArticleBJOG : an international journal of obstetrics and gynaecology2026
Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study.
Article in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association Between Maternal Angiogenic Markers in Hypertensive Disorders of Pregnancy and Neonatal Growth and Body Composition.Nutrients · 2026Article
- Beyond Diagnostic Cut-Offs: Associations Between the sFlt-1/PlGF Ratio and Perinatal Outcomes in Low-Risk Term Pregnancies.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt1) are two biomarkers associated with placental function and the sFlt-1/PlGF ratio is frequently used for risk assessment and prediction of preeclampsia in pregnancy.
objectiveTo assess the association between elevated sFlt-1/PlGF ratio and adverse neonatal outcomes in pregnancies with suspected preeclampsia.
designRetrospective cohort study.
settingA tertiary centre in Hong Kong. POPULATION: 162 singleton neonates delivered between January 2020 and May 2023 from pregnancies complicated by suspected preeclampsia and sFlt-1/PlGF taken within 4 weeks before delivery.
methodsPregnant women with suspected preeclampsia were recruited with analysis of serum Flt-1 and PlGF. Neonatal outcomes were compared between neonates from pregnancies with sFlt-1/PlGF ratio ≥ 85 (high-risk group) and < 85 (low-risk group).
main outcome measuresNeonatal outcomes including growth, respiratory, gastrointestinal, and metabolic complications.
resultsLogistic regression analysis showed that after adjustment for gestational age, preeclampsia and newborn sex, sFlt-1/PlGF ratio ≥ 85 was significantly associated with small-for-gestation (SGA; aOR = 2.52, 95% C.I. = 1.12-5.60), feeding intolerance (aOR = 3.03, 95% C.I. = 1.01-9.09), need for parenteral nutrition (PN; aOR = 11.19, 95% C.I. = 2.23-56.29), prolonged PN (aOR = 6.92, 95% C.I. = 1.43-33.39), hospitalisation over 7 and 30 days (aOR = 3.62, 95% C.I. = 1.20-10.87 and aOR = 7.04, 95% C.I. = 1.08-45.80 respectively). Linear regression showed a significant association between sFlt-1/PlGF ratio and duration of respiratory support, PN and duration of hospital stay.
conclusionsAn elevated maternal sFlt-1/PlGF ratio within 4 weeks of delivery is significantly associated with adverse neonatal outcomes including SGA, gastrointestinal complications, prolonged parenteral nutrition and prolonged hospitalisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.